Global Atrial Fibrillation Market
Report is a professional and in-depth research report on the world’s major
regional market conditions of the market, focusing on the main regions and the
main countries (North America, Europe, APAC, MEA and South America). The report
focuses on leading industry players with information such as company profiles,
products and services offered, financial information of last 3 years, key
development in past five years.
Atrial Fibrillation Market
is expected to garner $8,319 million by 2022, registering a CAGR of 13.0%
during the period 2014 - 2022. Non-surgical devices segment dominated the
overall market in 2015. North America was the leading geographic segment in
global atrial fibrillation devices market in 2015, and is expected to maintain
its leading position throughout forecast period.
Rise in prevalence rate of
atrial fibrillation in geriatric population, technological advancements in
devices, improvement of healthcare infrastructure in developing countries,
development of minimally invasive procedures, and increase in patient awareness
propel the market growth. However, dearth of skilled professionals and
unfavorable preference to pharmaceutical drugs hamper the growth of the market.
Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/479
Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/479
Key players have adopted product development as their key
strategy to cater to the changing needs of the industry.
Major players that operate in this market include.
·
Abbott Laboratories
·
Johnson & Johnson
·
MicroPort Scientific Corporation
·
Boston Scientific Corporation
·
St. Jude Medical Inc.
·
Medtronic plc
·
Biotronik SE & Co. KG
·
Koninklijke Philips N.V.
·
Siemens AG
·
AtriCure Inc
Catheter ablation is the highest revenue contributor and is
expected to grow at the highest CAGR of 13.8% in the analysis period. This
growth is owing to the technological advancements such as cryoFORM, which
offers increased flexibility that allows easy manipulation and treatment during
surgical process. In addition, increase in preference of catheter ablation for
cardiac arrhythmia treatment over other devices as this is the safer and
minimally invasive surgical procedures used for the treatment of atrial
fibrillation.
Asia-Pacific is expected to be the fastest
growing region with a CAGR of 14.7% during the forecast period. Japan accounted
for the highest share of the total Asia-Pacific market in 2015; while China is
poised to grow at highest CAGR during the analysis period (20162022). This
growth in this region is attributed to the rise in the prevalence of cardiac
arrhythmia in developing countries (such as India and China) owing to the large
geriatric population.
For More
Information @ https://www.alliedmarketresearch.com/purchase-enquiry/479
Key findings of the Atrial Fibrillation Market
- North America dominated the
market of atrial fibrillation and is expected to maintain its lead
throughout the forecast period, with a CAGR of 12.1%
- By
country, U.S. generates the highest revenue in 2015
- Asia-Pacific
is the fastest growing market and is estimated to grow at a CAGR of 14.7%
- Japan
accounted for more than one-third share of the Asia-Pacific atrial
fibrillation devices market in 2015
- The
non-surgical equipment segment dominated in 2015, occupying largest
revenue share and is anticipated to grow at a CAGR of 12.5%
- Catheter
ablation (sub segment for surgical equipment) accounted for largest market
share in 2015 and is anticipated to grow at a CAGR of 13.8%
- Cryoablation,
a sub type of catheter ablation, is projecting the highest CAGR of 14.6%
during the study period
North America accounted for the major share in
the global atrial fibrillation devices market in 2015, and is expected to
maintain its leading position throughout forecast period. This is attributable
to the increase in prevalence of atrial fibrillation in geriatric population
and high adoption of advanced technologies for the treatment of AF.
Access Full Summery @ https://www.alliedmarketresearch.com/press-release/atrial-fibrillation-market.html
No comments:
Post a Comment